Abstract
The recent EC - Biotech case highlights the emerging regulatory divide between WTO Members and reveals a deepening crisis over issues of science and governance in the world trading system. This article focuses on the potential role that social science expertise might play as an analytical tool in understanding trade disputes involving scientific expertise relating to matters of risk assessment and polycentric decision-making. Particular consideration is given to the paradigm of 'post-normal' science, which pertains in situations where competent national authorities have to frame and implement policies before all the (scientific) facts are known. As the amicus curiae brief by a group of five social scientists before the Panel in EC - Biotech demonstrates, where there is a high degree of scientific uncertainty, as in the case of GM products, post-normal science can offer a valuable means of framing the dispute in a broader societal context than the sound science approach, which is used when assessing health, safety and environmental risks under the SPS Agreement.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
